Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors

BACKGROUND: Molecularly targeted therapies using receptor inhibitors, small molecules or monoclonal antibodies are routinely applied in oncology. Verification of target expression should be mandatory prior to initiation of therapy, yet, determining the expression status is most challenging in recurr...

Full description

Saved in:
Bibliographic Details
Published in:J Transl Med
Main Authors: Schäfer, Niklas, Gielen, Gerrit H., Rauschenbach, Laurèl, Kebir, Sied, Till, Andreas, Reinartz, Roman, Simon, Matthias, Niehusmann, Pitt, Kleinschnitz, Christoph, Herrlinger, Ulrich, Pietsch, Torsten, Scheffler, Björn, Glas, Martin
Format: Artigo
Language:Inglês
Published: BioMed Central 2019
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6425567/
https://ncbi.nlm.nih.gov/pubmed/30894200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-019-1846-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items